Table 4.
Anti-angiogenic drugs in ongoing clinical trials for the treatment of pancreatic cancer and their respective targets.
| Drug | Combination | Phase | Primary Outcome | Status | ID |
|---|---|---|---|---|---|
| Apatinib | Camrelizumab | II | ORR (2 years) | Recruiting | NCT04415385 |
| Apatinib | Irinotecan plus S-1 | II | PFS (1 year) | Recruiting | NCT04101929 |
| Ramucirumab | mFOLFIRINOX | II | PFS (9 months) | Not recruiting | NCT02581215 |
| AZD4547 | - | II | ORR (3 years) | Recruiting | NCT02465060 |
| Erdafitinib | - | II | ORR (3 years) | Recruiting | NCT02465060 |
| Cetuximab | SNK01 | I/II | RP2D, ORR (12 months) | Not yet recruiting | NCT04464967 |
| Cetuximab | MRTX849 | I/II | Safety, PK, clinical activity | Recruiting | NCT03785249 |
| Bevacizumab | NANT | I/II | AE, SAE, ORR (1 year) | Not recruiting | NCT03387098 |
| Bevacizumab | Durvalumab, CV301, capecitabine | I/II | RP2D, PFS (8.5 months), PFS (4 months) | Not recruiting | NCT03376659 |
| Bevacizumab | NANT | I/II | AE, SAE, ORR (1 year) | Not recruiting | NCT03329248 |
| Bevacizumab | Gemcitabine, nab-paclitaxel, atezolizumab | I/II | ORR (3–5 years), AE | Recruiting | NCT03193190 |
| Bevacizumab | NANT | I/II | AE, SAE, ORR (1 year) | Not recruiting | NCT03136406 |
| Bevacizumab | Capecitabine, temozolomide | II | RR (18 months) | Not recruiting | NCT01525082 |
| Bevacizumab | Octreotide acetate, everolimus | II | PFS (3 years) | Not recruiting | NCT01229943 |
| TS-1 | Gemcitabine | II | DFS (24 months) | Recruiting | NCT02754180 |
| Nintedanib | - | I/II | MTD | Recruiting | NCT02902484 |
| Pazopanib | - | II | PFS (5 years) | Not recruiting | NCT01841736 |
| Pazopanib | Temozolomide | I/II | MTD, RP2D, ORR (2 months) | Not recruiting | NCT01465659 |
| Regorafenib | - | II | PFS (2 months) | Not recruiting | NCT02307500 |
| Regorafenib | - | II | PFS (6 months) | Not recruiting | NCT02259725 |
| Surufatinib | - | III | PFS (7 months) | Not recruiting | NCT02589821 |
| Pamrevlumab | Gemcitabine, nab-paclitaxel | III | OS (18 months), R0/R1 resections | Recruiting | NCT03941093 |
| Pamrevlumab | Gemcitabine, nab-paclitaxel | I/II | Safety, R0/R1 resections, TRR (24 weeks), OS, PFS (52 weeks) | Not recruiting | NCT02210559 |
| ENB003 | Pembrolizumab | I/II | AE, ORR (2 years) | Not yet recruiting | NCT04205227 |
ORR, objective response rate; PFS, progression free survival; RP2D, recommended phase II dose; PK, pharmacokinetics; AE, adverse events; SAE, serious adverse events; RR, radiographic response; DFS, disease free survival; MTD, maximum tolerated dose.